Newer Drugs Not Cost-Effective for First-Line Diabetes Therapy Newer Drugs Not Cost-Effective for First-Line Diabetes Therapy

Costs of SGLT2 inhibitors and GLP-1 receptor agonists ' need to be lowered substantially ' to improve health outcomes and prevent health disparities in patients with type 2 diabetes, say researchers.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news